Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
10.00
+0.30 (3.15%)
Nov 3, 2026, 4:00 PM EST - Market closed
Absci Revenue
Absci had revenue of $318.00K in the quarter ending June 30, 2026, a decrease of -46.37%. This brings the company's total for the last twelve months to $1.56M, down -62.28% year-over-year. In the year 2025, Absci had annual revenue of $2.80M, down -38.24%. That makes Absci the 42,896th largest company in the world by revenue and 5,904th in the United States.
Revenue (ttm)
$1.56M
Revenue Growth
-62.28%
P/S Ratio
1,123.57
Revenue / Employee
$11,150
Employees
140
Market Cap
1.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.80M | -1.73M | -38.24% |
| Dec 31, 2024 | 4.53M | -1.18M | -20.71% |
| Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
| Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
| Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
| Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
| Dec 31, 2019 | 2.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 717.00M |
| UroGen Pharma | 188.73M |
| Nuvation Bio | 169.90M |
| Intellia Therapeutics | 59.51M |
| Stoke Therapeutics | 28.21M |
| Generate Biomedicines | 26.48M |
| Maze Therapeutics | 20.00M |
| uniQure | 18.67M |
ABSI News
- 5 days ago - Absci initiated with a Buy at Jefferies - TheFly
- 7 days ago - Absci to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Absci price target raised to $20 from $16 at KeyBanc - TheFly
- 21 days ago - Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026 - GlobeNewsWire
- 22 days ago - Absci price target raised to $15 from $14 at JPMorgan - TheFly
- 5 weeks ago - Absci announces preliminary details for Phase 2 Storyline trial of ABS-201 - TheFly
- 5 weeks ago - Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - GlobeNewsWire
- 6 weeks ago - Absci Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts